Search

Your search keyword '"Kama, Jibrin A"' showing total 11 results
Start Over Author "Kama, Jibrin A"
11 results on '"Kama, Jibrin A"'

1. A Model for Accelerating Access to Care and Treatment for Children and Adolescents Living with HIV in Nigeria, Tanzania, Uganda, and Zambia: The Faith-Based Action for Scaling-Up Testing and Treatment for the Epidemic Response (FASTER) Initiative

Author

Oliver, Daniel, primary, Mabirizi, David, additional, Hast, Marisa, additional, Alwano, Mary Grace, additional, Chungu, Chalilwe, additional, Kelemani, Alphonce, additional, Mbanefo, Chizoba, additional, Gross, Jessica, additional, Parris, KaeAnne, additional, Dowling, Stephanie, additional, Clark, Adele, additional, Williams, Amanda, additional, Simao, Lauren, additional, Amole, Carolyn, additional, Suggu, Kanchana, additional, Kama, Jibrin, additional, Mpasela, Felton, additional, Mtui, Leah, additional, Nabitaka, Vennie, additional, Saunders, Renée, additional, Williamson, Dhelia, additional, Rivadeneira, Emilia D, additional, Hrapcak, Susan, additional, Nantume, Sophie, additional, Nazziwa, Esther, additional, Itoh, Megumi, additional, Machage, Edward, additional, Onyenuobi, Chibuzor, additional, Munthali, Gloria, additional, Rwebembera, Anath, additional, Mwiya, Mwiya, additional, Katureebe, Cordelia, additional, Ikpeazu, Akudo, additional, and Fenn, Thomas, additional

Published
2023
Full Text
View/download PDF

2. Human papillomavirus testing using existing nucleic acid testing platforms to screen women for cervical cancer: implementation studies from five sub-Saharan African countries

Author

Joseph, Jessica, primary, Demke, Owen, additional, Ameyan, Lola, additional, Bitilinyu-Bango, Joseph, additional, Bourgoin, Blandine, additional, Diop, Mamadou, additional, Guèye, Babacar, additional, Kama, Jibrin, additional, Lubega, Marvin, additional, Madzima, Bernard, additional, Maparo, Tatenda, additional, Mhizha, Tasimba, additional, Musoke, Andrew, additional, Nabadda, Susan, additional, Phiri, Twambilire, additional, Tchereni, Timothy, additional, Wiwa, Owens, additional, Hariharan, Karen, additional, Peter, Trevor, additional, and Khan, Shaukat, additional

Published
2023
Full Text
View/download PDF

3. Patient Navigators: an innovative approach to improve hepatitis c case finding leveraging existing human immunodeficiency virus service delivery models to reach last mile patients in Nasarawa State, Nigeria

Author

Agwuocha, Chukwuemeka, primary, Adisa, Olayinka, additional, Nwobi, Onyeka, additional, Akanmu, Muhammad-Mujtaba, additional, Boeke, Caroline, additional, Witschi, Magdalena, additional, Azania, Amy, additional, Kama, Jibrin, additional, Lufadeju, Folu, additional, and Wiwa, Owens, additional

Published
2022
Full Text
View/download PDF

8. The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease

Author

Frentzel Stefan, Hoyer Daniel, Betschart Claudia, Bleckmann Dorothee, Kama Jibrin A, Dorsey Kate, Chopra Vanita, Connor Teal, Fox Jonathan H, DiFiglia Marian, Paganetti Paolo, and Hersch Steven M

Subjects
Neurology. Diseases of the nervous system, RC346-429, Geriatrics, RC952-954.6
Abstract

Abstract Background Huntington's disease (HD) is a progressive neurodegenerative disorder caused by a CAG repeat expansion within the huntingtin gene. Mutant huntingtin protein misfolds and accumulates within neurons where it mediates its toxic effects. Promoting mutant huntingtin clearance by activating macroautophagy is one approach for treating Huntington's disease (HD). In this study, we evaluated the mTOR kinase inhibitor and macroautophagy promoting drug everolimus in the R6/2 mouse model of HD. Results Everolimus decreased phosphorylation of the mTOR target protein S6 kinase indicating brain penetration. However, everolimus did not activate brain macroautophagy as measured by LC3B Western blot analysis. Everolimus protected against early declines in motor performance; however, we found no evidence for neuroprotection as determined by brain pathology. In muscle but not brain, everolimus significantly decreased soluble mutant huntingtin levels. Conclusions Our data suggests that beneficial behavioral effects of everolimus in R6/2 mice result primarily from effects on muscle. Even though everolimus significantly modulated its target brain S6 kinase, this did not decrease mutant huntingtin levels or provide neuroprotection.

Published
2010
Full Text
View/download PDF

9. The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease

Author

Fox, Jonathan H, primary, Connor, Teal, additional, Chopra, Vanita, additional, Dorsey, Kate, additional, Kama, Jibrin A, additional, Bleckmann, Dorothee, additional, Betschart, Claudia, additional, Hoyer, Daniel, additional, Frentzel, Stefan, additional, DiFiglia, Marian, additional, Paganetti, Paolo, additional, and Hersch, Steven M, additional

Published
2010
Full Text
View/download PDF

11. Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1

Author

Zucker, Birgit, primary, Luthi-Carter, Ruth, additional, Kama, Jibrin A., additional, Dunah, Anthone W., additional, Stern, Edward A., additional, Fox, Jonathan H., additional, Standaert, David G., additional, Young, Anne B., additional, and Augood, Sarah J., additional

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results